Back pain is one of the most common — and most disruptive — health burdens worldwide. An estimated 80% of adults will experience clinically significant back pain at some point in their lives, and a substantial proportion progress to chronic, life-limiting disability. For many, the underlying driver is degenerative disc disease — a progressive breakdown of the intervertebral discs that cushion the spine, often accompanied by herniation, nerve compression, and persistent inflammation. For decades, the conventional pathway has been linear and limited: anti-inflammatory medication, epidural steroid injections, physical therapy, and eventually spinal surgery. Mesenchymal Stem Cell therapy offers a fundamentally different approach — one focused not on managing pain alone, but on supporting the spine's own regenerative biology.

Understanding what is actually happening in your spine

Healthy spinal discs are composed of a tough outer ring — the annulus fibrosus — and a gel-like inner core, the nucleus pulposus. These structures bear axial load, allow flexion and rotation, and shield spinal nerves as they exit the vertebral column. Degenerative disc disease is the progressive breakdown of this system — driven not just by mechanical wear, but by chronic low-grade inflammation within the disc space. Inflammatory cytokines such as IL-1β, IL-6, and TNF-α are produced by stressed disc cells, accelerate matrix degradation, and sensitize adjacent nerve roots — creating the cycle of pain, muscle spasm, and functional limitation familiar to anyone with chronic back problems.

This matters because traditional treatments target the symptom (pain) without addressing the process (disc degeneration and neuroinflammation). MSC therapy, by contrast, intervenes at the inflammatory and regenerative level — addressing both the pain experience and the underlying spinal biology.

Cross-section showing herniated intervertebral disc with nucleus pulposus compressing spinal nerve root
Degenerative disc disease is more than mechanical wear — chronic inflammation drives the breakdown cycle that MSC therapy targets at its source.

How MSC therapy works in the spine

When clinical-grade Mesenchymal Stem Cells are delivered to a degenerated disc or the surrounding epidural space — either via precision injection or systemic infusion — they engage the inflammatory environment in several coordinated ways:

1. They quiet disc inflammation

MSCs respond to the high cytokine environment by releasing anti-inflammatory mediators (TSG-6, PGE2, IDO) that interrupt the degenerative cascade. Within the disc space and surrounding tissue, this can begin reducing pain and radicular symptoms in the early weeks after treatment.

2. They support disc matrix preservation

MSCs secrete growth factors (TGF-β, IGF-1, BMP-7) that signal resident disc cells to maintain proteoglycan and collagen matrix integrity, potentially slowing or partially reversing disc height loss.

3. They modulate neuroinflammation

When a herniated disc compresses a nerve root, the resulting inflammation — not just mechanical pressure — drives the radiating pain, numbness, and weakness of sciatica. MSCs influence local immune cell populations, encouraging a shift from pro-inflammatory to regenerative phenotypes that can reduce nerve root irritation.

4. They support surrounding soft tissue

Paraspinal muscles, ligaments, and facet joints all benefit from MSC paracrine signalling — relevant in the many patients whose back pain stems from a combination of disc, facet, and muscular dysfunction.

What MSC therapy does NOT do

It is important to set honest expectations. MSC therapy does not regrow a completely collapsed disc. It does not reverse severe spinal stenosis or correct structural deformities. What it does is reduce discogenic inflammation, support remaining disc matrix, ease radicular pain, and may delay or potentially avoid the need for spinal surgery in carefully selected candidates with mild-to-moderate degenerative changes.[1]

Who is a good candidate?

The strongest results from MSC therapy for back pain come from patients with mild to moderate degenerative disc disease — typically Pfirrmann grades II, III, and early IV on MRI. These are patients who:[2]

Patients with end-stage disc collapse (severe Pfirrmann grade V), significant spinal instability, or progressive neurological deficits (foot drop, bowel/bladder dysfunction) are typically less suitable for regenerative therapy alone and should be evaluated by a spine surgeon. A reputable clinic will tell you this honestly. The role of the consultation is to determine candidacy through MRI review, neurological examination, and functional assessment.[3]

What the treatment process looks like

At a clinical-grade centre, a typical journey for spine-focused MSC therapy follows a structured path:

Step 1: Consultation and assessment

Medical history review, spinal MRI, neurological examination, inflammatory bio-markers, and functional assessment. The goal is to confirm candidacy and identify the optimal protocol — whether intradiscal injection, epidural delivery, IV infusion, or a combination.

Step 2: Protocol design

The clinical team determines: dose, delivery route (intradiscal injection, transforaminal epidural, IV infusion, or combined), frequency (single session vs. series), and adjunct therapies (physiotherapy, core stabilization, lifestyle adjustments).

Step 3: Treatment delivery

Intradiscal and epidural injections are performed under fluoroscopy or CT guidance for precision placement. Sessions are outpatient, generally 60–90 minutes including preparation. Patients walk out the same day.

Step 4: Recovery period

Light activity restrictions for 48–72 hours, then a graduated return to normal mobility. Most protocols include a structured physiotherapy programme — core stabilization, postural retraining, and gradual loading — alongside the cellular therapy.

Step 5: Outcome monitoring

Follow-up at 4, 12, and 24 weeks tracks pain (using validated scales like VAS and ODI — Oswestry Disability Index), function, range of motion, and where appropriate, repeat MRI.

Physician performing fluoroscopy-guided stem cell injection into patient's lumbar disc space
Image-guided intradiscal injection ensures precise placement of MSCs within the degenerated disc for maximum local effect.

Realistic timelines: what to expect when

Cellular therapy is not a pharmaceutical — it does not deliver an instant effect. Most patients experience the response in three identifiable phases:[4]

2–4 weeks Initial reduction in inflammation and radicular discomfort
8–12 weeks Functional improvement: mobility, pain reduction, daily activity
6–12 months Sustained benefit window; many patients return for maintenance

Outcomes vary by patient, severity of disc degeneration, MSC source quality, dosing, and the structure of the surrounding rehabilitation programme. A reputable clinic will be transparent about typical response rates and the proportion of patients who experience strong vs. moderate vs. limited benefit.[5]

Safety and what every patient should know

When delivered with clinical-grade cells, image-guided injection technique, and appropriate clinical oversight, MSC therapy for back pain has an excellent safety profile. The most common side-effects are local: temporary post-injection soreness, mild swelling, or stiffness for 24–72 hours. Serious adverse events are rare in published literature.[6]

The biggest preventable risk in this field is not the therapy itself — it is unregulated providers using non-clinical-grade cells with unverified sterility, identity, or potency. This is why patients should always confirm: source of the cells, laboratory certifications, and access to a Certificate of Analysis for the dose being administered.[7]

For the right patient — with mild to moderate disc degeneration and a goal of preserving spinal function — MSC therapy can be a meaningful alternative to a future of escalating medication and eventual surgery.

— VELAR Clinical Team

The VELAR approach to spinal regeneration

Spine-focused protocols at VELAR Center begin with comprehensive MRI review, neurological assessment, and bio-marker evaluation to confirm candidacy and tailor dosing. Each patient's protocol uses clinical-grade Wharton's jelly–derived MSCs (≥95% MSC marker expression, >90% post-thaw viability), delivered via image-guided intradiscal injection, epidural delivery, IV infusion, or combined protocol depending on the indication. Every session is led by an experienced clinician, paired with structured rehabilitation, and monitored across the 1, 3, and 6-month milestones.[8]

If you are considering regenerative therapy for back pain, the most important first step is an honest assessment of your specific candidacy — and a clear understanding of what realistic outcomes look like for your stage of disc disease.

References

  1. Sakai D, Schol J. Cell therapy for intervertebral disc repair: clinical perspective. Journal of Orthopaedic Translation. 2017;9:8-18. doi:10.1016/j.jot.2017.02.002 ↩
  2. Pfirrmann CW, Metzdorf A, Zanetti M, Hodler J, Boos N. Magnetic resonance classification of lumbar intervertebral disc degeneration. Spine. 2001;26(17):1873-1878. doi:10.1097/00007632-200109010-00011 ↩
  3. Orozco L, Soler R, Morera C, Alberca M, Sánchez A, García-Sancho J. Intervertebral disc repair by autologous mesenchymal bone marrow cells: a pilot study. Transplantation. 2011;92(7):822-828. doi:10.1097/TP.0b013e3182298a15 ↩
  4. Pettine KA, Murphy MB, Suzuki RK, Sand TT. Percutaneous injection of autologous bone marrow concentrate cells significantly reduces lumbar discogenic pain through 12 months. Stem Cells. 2015;33(1):146-156. doi:10.1002/stem.1845 ↩
  5. Centeno C, Markle J, Dodson E, et al. Treatment of lumbar degenerative disc disease-associated radicular pain with culture-expanded autologous mesenchymal stem cells: a pilot study on safety and efficacy. Journal of Translational Medicine. 2017;15(1):197. doi:10.1186/s12967-017-1300-y ↩
  6. Meisel HJ, Agarwal N, Hsieh PC, et al. Cell therapy for treatment of intervertebral disc degeneration: a systematic review. Global Spine Journal. 2019;9(1 Suppl):39S-52S. doi:10.1177/2192568219829024 ↩
  7. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317. doi:10.1080/14653240600855905 ↩
  8. Noriega DC, Ardura F, Hernández-Ramajo R, et al. Intervertebral disc repair by allogeneic mesenchymal bone marrow cells: a randomized controlled trial. Transplantation. 2017;101(8):1945-1951. doi:10.1097/TP.0000000000001484 ↩
  9. Richardson SM, Kalamegam G, Pushparaj PN, et al. Mesenchymal stem cells in regenerative medicine: focus on articular cartilage and intervertebral disc regeneration. Methods. 2016;99:69-80. doi:10.1016/j.ymeth.2015.09.015 ↩
  10. Amirdelfan K, Bae H, McJunkin T, et al. Allogeneic mesenchymal precursor cells treatment for chronic low back pain associated with degenerative disc disease: a prospective randomized, placebo-controlled 36-month study of safety and efficacy. Spine Journal. 2021;21(2):212-230. doi:10.1016/j.spinee.2020.10.004 ↩
  11. Mochida J, Sakai D, Nakamura Y, Watanabe T, Yamamoto Y, Kato S. Intervertebral disc repair with activated nucleus pulposus cell transplantation: a 3-year, prospective clinical study of its safety. European Spine Journal. 2015;24(9):1948-1954. doi:10.1007/s00586-015-4009-8 ↩
  12. Yoshikawa T, Ueda Y, Miyazaki K, Koizumi M, Takakura Y. Disc regeneration therapy using marrow mesenchymal cell transplantation: a report of two case studies. Spine. 2010;35(11):E475-480. doi:10.1097/BRS.0b013e3181cd2cf4 ↩